CoChat

Cychlorphine (N-Propionitrile Chlorphine): An Emerging Benzimidazolone Synthetic Opioid and Its Implications for Overdose Recognition and Management

Open access

The DOI matches its Crossref record; 6 of the 8 references it cites were found in a registry or an index; 10 of the 33 sources its claims cite were checked for support.

Abstract

Robert B Raffa,1,2 Frank Breve,3 Joseph V Pergolizzi Jr,2,4 Eugene Vortsman,5 Giustino Varrassi61School of Pharmacy, Temple University (Emeritus), Philadelphia, PA, USA; 2Research and Development, Enalare Therapeutics, Mullica Hill, NJ, USA; 3Clinical Pharmacy, Mid Atlantic PharmaTech Consultants, Ventnor City, NJ, USA; 4Anesthesiology, NEMA Research, Naples, FL, USA; 5Emergency Department, Long Island Jewish Medical Center at Northwell Health, New York, NY, USA; 6VIBRO, Fondazione Paolo Procacci, Roma, ItalyCorrespondence: Robert B Raffa, Email robert.raffa@gmail.com

Overview

CoChat Summary

TL;DR

Cychlorphine (N-propionitrile chlorphine) is an emerging benzimidazolone “orphine” synthetic opioid detected in fatal overdoses and toxicology cases, with potent µ-opioid receptor agonism and major detection gaps in standard screens. Naloxone is still expected to work as for other MOR agonists, though repeat dosing may be needed and co-intoxicants can complicate reversal.

Key findings

  • Cychlorphine is a benzimidazolone/orphine NSO, not a fentanyl analog, nitazene, or morphinan; CFSRE first detected it in August 2024 with confirmatory identification in September 2024, and DEA reported its first US laboratory detection in Florida in April 2024. By end of February 2026, DEA laboratories had identified it in 22 samples nationally.
  • The CFSRE January 2026 alert reported N-propionitrile chlorphine in 25 blood specimens from fatal overdoses—21 in the United States and 4 in Canada—and it was the sole opioid identified in 11 of those 25 cases. NMS Labs tentatively identified it in more than 100 toxicology cases; as of March 2026, at least 24 states reported overdoses or deaths linked to cychlorphine, including 19 confirmed deaths in East Tennessee.
  • Preclinical data on chlorphine and related analogs show nanomolar MOR affinity, with chlorphine having the highest binding affinity among the series (Ki = 1.92 nM), potent antinociception, and pronounced respiratory depression; naloxone pre-treatment (6 mg/kg i.p.) only partially reversed respiratory depression for some compounds. Cychlorphine is estimated to be ~10-fold more potent than fentanyl.
  • Standard hospital immunoassays and fentanyl/nitazene test strips do not detect benzimidazolone NSOs; LC-MS/MS with validated reference standards is required. The paper states there is no published clinical evidence that naloxone is ineffective for cychlorphine overdose, and the only peer-reviewed human case report—a 36-year-old man with apnea, bradycardia, hypothermia, and partial naloxone response—does not mention pupil findings.

Methods

  • The paper is a narrative synthesis/commentary rather than a primary study; no formal methods section, systematic review protocol, or statistical analysis is reported.
  • It draws on cited public alerts and surveillance data (CFSRE, DEA, NMS Labs, UNODC), preclinical in vitro/in vivo characterization of brorphine and analogs, and one peer-reviewed human case report.
  • Main analysis is narrative integration of pharmacology, forensic detection data, and clinical management considerations for overdose recognition and naloxone use.

Limitations

  • Stated in text: no published clinical evidence supports the claim that naloxone is ineffective for cychlorphine; the “naloxone was not able to completely block” finding comes from a pre-treatment blocking design, not rescue administration. No published paper or case report explicitly records pupil size in a cychlorphine overdose victim, and standard immunoassays miss the compound, so deaths are systematically undercounted.
  • Stated in text: cychlorphine is not federally scheduled in the United States, and its status under the Federal Analog Act as applied to benzimidazolone structures has not been definitively resolved.
  • Evident from text: the clinical and epidemiological conclusions rely heavily on public alerts, surveillance counts, and extrapolation from chlorphine/brorphine analogs to cychlorphine, with limited human clinical data and no primary clinical trial or systematic review.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2147/jpr.s620907

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

8 Valid · 3 Not valid · 19 Not checked · 8 Own results and interpretations

19 more claims · 2 with their cited sources checked

Create a free account to see all 38 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 11
  • Probably not a substantial claim. 3

Create a free account to see these claims.

Citations

Cites

Show all 6 references

Metadata

Authors
Raffa, R. B., Breve, F., Pergolizzi, J. V., Vortsman, E., & Varrassi, G.
Affiliations
  • Temple University (US)
  • Nema Research (United States) (US)
  • Northwell Health (US)
  • Fondazione Paolo Procacci (IT)
Corresponding author
Raffa, Robert B
Venue
Journal of Pain Research
Published
2026-07
Volume
Volume 19
Pages
1-3
ISSN
1178-7090 (ISSN-L)
OpenAlex
W7167795840
Cited by
2
References
8
Citations by year
2026: 2
Type
journal article
Language
en
Open access
Locations
  • Journal of Pain Research (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (acceptedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
  • Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
Keywords
benzimidazolone, synthetic opioids, opioid overdose, overdose management, opioid analgesics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.